Introduction
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide. 1 Around 70% patients of HCC are diagnosed at an advanced stage of the disease, and are not eligible for curative treatments, such as liver resection, ablation, and transplantation. The median overall survival of advanced HCC without curative treatment is between 4 and 10 months. 2 There are currently limited available treatments for advanced HCC and their survival benefits remain unsatisfactory. 3, 4 Oncolytic poxvirus belongs to the oncolytic virus (OV) family. OVs are an emerging class of cancer therapeutics that have shown great promise in treating HCC. 5 OVs are engineered to replicate selectively in and destroy cancer cells by multiple mechanisms of action. 6 Currently, the choice of route of administration for oncolytic poxvirus delivery is limited to intratumoral (IT) and intravenous (IV) injections. 7, 8 The efficacy of IV injection is often compromised by neutralizing antibodies in the circulation, 9 and IT injection is superior to IV injection in terms of targeting disease but IT injection has limited value when tumors are inaccessible or scattered. Hepatic arterial infusion (HAI) is a routine practice for transarterial chemo-embolization and transarterial chemotherapy, and the recently US transarterial radioembolization requires HAI administration as well. A large retrospective study conducted among patients with colorectal cancer and liver metastases shows that chemotherapy administered via HAI resulted in almost 2 years longer survival than chemotherapy administered via other routes. 10 The benefit of HAI administration is impressive because HAI can introduce high doses of therapeutic agents directly to multiple tumor masses while keeping drugs' systemic toxicity to a minimum. HAI may become an attractive route of administration for OVs. However, the safety of HAI administration of OVs is of great concern, particularly after the tragic incident of a fatal systemic inflammatory response syndrome in a patient following adenoviral gene transfer.
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There have been a few preclinical and clinical studies on the safety of HAI of OVs, such as adenovirus, herpes simplex virus-1, and vesicular stomatitis virus (VSV), [12] [13] [14] but there is no safety information for the HAI administration of oncolytic poxvirus. In addition, it should be noted that 70% HCC patients have liver cirrhosis and/or other liver disorders; in a previous study conducted by Altomonte et al, the HAI administration of VSV showed no acute (up to 3 days) toxicity in rats with liver fibrosis. 15 In this study, we aimed to investigate the acute and chronic (up to 2-6 months) toxicity of HAI administration of oncolytic poxvirus in a rabbit model with normal liver function and in a rat model with N-nitrosomorpholin (NNM)-induced precancerous liver cirrhosis.
Materials and methods Virus
Oncolytic poxvirus with inactivation of thymidine kinase gene, was engineered from a Wyeth strain vaccinia virus (New York City Department of Health Laboratories) as described previously. 16 VV tk− was re-suspended in 0.1 mL of PBS for use. The injected virus doses in rabbit study were 1×10 8 and 1×10 9 pfu and in rat study 1×10 8 pfu.
rabbit study Eight New Zealand white rabbits (Samtako, Osan, Korea) with an average weight of 3 kg were randomly assigned to a low-(1×10 8 pfu) or a high-dose (1×10 9 pfu) group, 5 rabbits (2 were from the low-dose group) were followed up for 3 weeks, and the rest for 8 weeks. HAI was performed under fluoroscopic guidance (Integris H5000F, Philips, Bothell, WA, USA) via central auricular arteries as previously described. 17 In brief, an 18-gauge angiocath needle was inserted into the rabbits' central auricular artery (of right or left side). And a 2.0-F microcatheter (Progreat, Terumo, Tokyo, Japan) and a 0.016-inch guidewire (Meister, Asahi Intecc Co., Ltd, Aichi, Japan) were introduced into the central auricular artery under fluoroscopic guidance by interventional radiologists (Figure 1 ). The guidewire was advanced carefully into the left hepatic artery through the descending thoracic aorta. When the microcatheter tip was placed in the left hepatic artery, contrast medium (Omnipaque, GE Healthcare, Seoul, Korea) was injected intra-arterially, followed by (1×10 8 or 1×10 9 pfu) VV tk− and normal saline. Body weight was measured weekly until sacrifice, and blood samples were collected before injection and 1, 2, 3, and 8 weeks post injection for biochemical and hematological tests. All animal care, handling, and study procedures were in compliance with Institutional Animal Care and Use Committee (IACUC) guidelines from the Ministry of Food and Drug Safety. The animal study protocols were approved by the Pusan National University IACUC and performed at the Laboratory Animal Resource Center of Pusan National University, South Korea.
Immunofluorescence assay
Organs were harvested from all the rabbits after sacrifice and prepared as paraffin-embedded tissue slides. In addition, paraffin-embedded tissue slides of tumors (HT-29 and 
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Preclinical safety of hepatic arterial infusion of oncolytic poxvirus HCT-116) and non-tumor organs obtained from mice that received IT injections of VV tk− were used as positive and negative controls. The immunostaining was conducted using a M.O.M kit (FMK-2201, Vector, Burlingame, CA, USA), and the primary antibody was mouse anti-A56 monoclonal antibody (ABIN1606294, Antibodies-Online, Aachen, Germany), the secondary antibody was Alexa Fluor ® 488 antibody (A21204,Thermo Fisher Scientific, MA, USA). Fluorescence was monitored with an inverted research microscope (Eclipse Ti2, Nikon, Tokyo, Japan).
nnM rat study NNM (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) was diluted in tap water. And 8-week old female Sprague-Dawley rats (Samtako, Osan, Korea) weighing 200-230 g were given 120 mg/L NNM water for the first 4 weeks, and 200 mg/L for the following 4 weeks, and regular tap water for another 2 weeks. 18 After the NNM pretreatment, 26 rats remained alive, and 2 of the rats were sacrificed for a liver histopathologic examination, and 24 rats were randomly assigned to a treatment group (n=13) or a control group (n=11), to receive the first HAI of 1×10 8 pfu VV tk− or PBS under an open abdomen surgery. 19 The second HAI was given 24 weeks later for safety evaluation at a more advanced stage of the liver diseases because it is estimated that liver tumors develop between week 16 and 20 in this model, 18 and 2 weeks later all the rats were sacrificed. Body weight was measured weekly until death or sacrifice. Because the open surgery may impose a huge impact on the biochemical tests, blood samples were not collected for the first HAI, instead, they were collected 1 and 3 days prior to the second HAI, and 1, 3, 5, and 7 days afterwards for aspartate aminotransferase (AST) and alanine transaminase (ALT) tests, using AST and ALT activity assay kits (colorimetric/fluorometric) (ab105135 and ab105134, Abcam, Cambridge, UK).
statistical analysis
All data compared between 2 groups over different time points were analyzed using a linear mixed model analysis by SPSS software 21.0. A Kaplan-Meier survival curve was plotted and log-rank test was conducted using GraphPad Prism 5.03, a P-value 0.05 was considered statistically significant.
Results

Toxicity of hai administration of VV tk− in healthy rabbits
No rabbits died between the HAI and the sacrifice day. One week after HAI of VV tk− , we observed an average of 230 g transient body weight decrease in all but 1 rabbit from the low-dose group (Figure 2 ). We also observed transient changes in the liver and renal functions in more than half of the rabbits, but these rabbits showed complete recovery 1 week later ( Figure 3 ). In addition, the hematological changes were mild (Figure 4) , and the changes in body weight, liver, and renal functions were not significantly different between the 2 dose groups, or between female and male rabbits.
expression of a56 in rabbit organs
The immunofluorescence assay detected expression of A56 on the membrane of tumor cells, but not in other organs obtained from 2 different human tumor-bearing (HT-29 and HCT-116) mice that received IT injections of VV tk− . In contrast, A56 was not detected in any other non-tumor organs in the mice, neither was A56 detected in the rabbit organs ( Figure 5 ).
Toxicity of hai administration of VV tk− in nnM-induced liver cirrhotic rats
Histopathological examinations confirmed the establishment of liver cirrhosis in the 2 rats sacrificed after the NNM pretreatment ( Figure 6 ). Survival and body weight were monitored for 26 weeks after the first injection ( Figure 6 ). Three of the 13 rats in the VV tk− group and 3/11 in the PBS group died within 1 week after the first injection. After the second injection, 0/13 and 1/11 rats from the 2 groups, respectively, died within 1 week. By week 26, 5/13 rats in the VV tk− group and 2/11 in the PBS group survived. There was no statistical difference in survival between the 2 groups. One week after the first injection, the mean body weights were 101.2% 
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Preclinical safety of hepatic arterial infusion of oncolytic poxvirus (% of the baseline) for the VV tk− group and 95.6% for the PBS. Statistically, the body weight increase was slightly higher in the VV tk− group than in the PBS (P0.001). As the number of survival animals decreased, the body weight change became visually indistinguishable between the 2 groups. In addition, the AST levels measured before and after the second injections indicated no statistical difference between the 2 groups. In contrast, ALT levels were statistically lower in the VV tk− group than in the PBS group (Figure 7 ).
Discussion
To our knowledge, this is the first study that explored the safety of HAI administration of high doses of oncolytic poxvirus, particularly under conditions of liver cirrhosis. And it is the first study that used the expression of A56, an oncolytic poxvirus-specific membrane protein as a marker for preclinical safety evaluation.
It was estimated that the doses of oncolytic poxvirus administered to the 2 animal models were equivalent to 1×10 9 -1.5×10
10 pfu in humans, higher than the maximum dose (3×10 9 pfu) of JX-594 (an oncolytic poxvirus) that was used in clinical trials. 7 In the rabbit study, we observed transient changes in body weight and organ functions after the HAI of VV tk− in both high-and low-dose groups. However, these changes were unlikely due to the virus infection because none of the changes showed dose dependency. Instead, they were more likely physiological responses to the invasive procedure of HAI, as similar changes were observed in other HAI studies as well. 20, 21 In the rat study, the AST/ALT measured before and after the second HAI 6 study design (upper) and study results (lower) of the rat study. Masson Trichrome histological examination was conducted in liver tissue obtained from 2 rats (at week 0) that finished the NNM pretreatment, to confirm the formation of liver cirrhosis. Survival and body weight were monitored between week 0 and 26. Survival was not significantly different (P=0.388) between the 2 groups, P-value was obtained using log-rank test, and body weight increase (% of baseline) was significantly higher in the VV tk− group than the PBs one, P-value was obtained using linear mixed model analysis (P0.001). , and (C) rats with nnM-induced precancerous liver cirrhosis after the second hai of PBs. Abbreviations: hai, hepatic arterial infusion; nnM, n-nitrosomorpholin.
(the second HAI received little impact from surgery) were not different, which further proves that HAI of VV tk− is unlikely to cause any acute liver toxicity.
In vitro and in vivo markers that are commonly used for monitoring OVs include the following: 1) overall tumor genes' expression, 2) specific genes' expression in tumor cells, and 3) transgenes introduced into the viral genes. 22 And the recently developed fourth class of markers are viral genes, such as A56 that was used in this study. A56 is expressed exclusively on the membrane of cells that are infected by poxvirus, 23 and because oncolytic poxvirus VV tk− was designed to selectively infect cancer cells, in our study, A56 was only detected in tumor tissues but not in other non-tumor tissues after HAI administration of high doses of VV tk− , suggesting that HAI is a safe route of administration with regards to organ accumulation and toxicity. In future preclinical studies, A56 can be particularly valuable in monitoring oncolytic poxvirus replication status in tumor tissues. A56 expression data together with the kinetic data (eg, viral load in the circulation) can be important in developing pharmacokinetic-pharmacodynamic models for oncolytic poxvirus. Notably, the positive and negative controls for A56 used in this study were obtained from humanized tumor mice but not from rabbits, however, we assume the detection of mammalian-expressed vaccinia virus protein A56 is unlikely influenced by animal species. 24 NNM has been used to develop liver cirrhotic HCC animal models; 18 in this study, it was used to replicate chronic precancerous liver cirrhosis and its progression. The rats that received HAI of VV tk− did not demonstrate symptoms of acute toxicity (AST/ALT increase) or chronic toxicity (body weight decrease over 26 weeks). It should be noted that the AST/ALT tests were conducted after the second HAI and may have not accurately reflected the acute toxicity of the first HAI, because the VV tk− from the second HAI was likely to have been greatly eliminated by the anti-vaccinia neutralizing antibody that was developed after the first HAI. 25 However, because 3 rats in both the VV tk− and PBS control groups died within a day after the first HAI, we speculated that the VV tk− treatment was not more toxic than the PBS control, and these deaths were likely due to the burden of the open surgery that was conducted at the first HAI. From over a week after the first injection to the end of the study, more than half of the rats died from both groups, likely due to progression of disease. However, we did not observe more toxicity or deaths in the VV tk− group, on the contrary, the overall survival in the VV tk− group (5/13) seems to be superior to the PBS control group (2/11) although there is no statistical significance (log rank: P=0.388). The non-significance is Drug Design, Development and Therapy 2018:12 submit your manuscript | www.dovepress.com
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Preclinical safety of hepatic arterial infusion of oncolytic poxvirus probably because the sample sizes were too small and all the rats were sacrificed 2 weeks after the second HAI and there were not enough data to demonstrate any further survival benefit. What's more, the body weight changes and ALT tests were significantly more favorable in the VV tk− group than in the PBS (P0.05). Surprisingly, the livers obtained from sacrificed rats in the VV tk− group looked more like normal livers than cirrhotic ones. In contrast, livers obtained from sacrificed rats in the PBS group had developed visible multiple tumors (Figure 8 ). Because it was not our primary objective to evaluate the treatment efficacy in this study, the rats were sacrificed after the second HAI administration and the rat organs were not harvested for histopathological examinations. We have conducted other studies to test the efficacy of VV tk− in preventing and reducing the progression of NNM-induced liver diseases, and will report the results soon.
Conclusion
Administration of high doses of oncolytic poxvirus via HAI may cause a transient liver function change (which is likely due to the HAI procedure), but is unlikely to cause any dosedependent or liver cirrhosis-related acute or chronic toxicity, neither will it cause accumulation of the virus in any nontumor organs. Therefore, we suggest that HAI of oncolytic poxvirus can be vastly explored for its therapeutic potency in HCC patients in future studies.
Author contributions
Eun Jin Ryu and Tae-Ho Hwang designed the rabbit study. Eun Jin Ryu, Cy Hyun Kim, and Miyoung Kim conducted the rabbit study. Euna Cho and Mong Cho designed the rat study. Ung Bae Jeon conducted the angiography and Euna Cho conducted the rest of the rat study. All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.
Disclosure
Part of the data in this study is going to be submitted for an investigational new drug application by Bionoxx Inc. The authors have no conflicts of interest to declare in this work.
